

Stretching the Limits of Naloxone: Sufentanil and Naloxone-Resistant Contaminants in the Illicit Drug Supply

Enalare Therapeutics Inc.

Poster #3148

BACKGROUND

The primary risk in the current overdose crisis stems from the contamination of the illicit drug supply with substances that are resistant to standard naloxone dosing. The growing presence of sufentanil in the illicit supply—which often goes undetected and mixed with other substances—poses a substantial risk for rapid and profound respiratory depression, which can be more difficult to reverse due to the high receptor affinity and longer duration of action compared to naloxone.

While naloxone remains the first-line antidote for opioid toxicity, higher or repeated dose may be required for sufentanil overdose, and the duration of naloxone's effect may be shorter than that of sufentanil, necessitating prolonged monitoring and repeated administration.[1-3] This is further complicated by the frequent co-occurrence of naloxone-resistant substances such as xylazine, or “Tranq,” and synthetic benzodiazepines, which do not respond to opioid antagonists and can cause persistent CNS and respiratory depression even after opioid reversal.[4-8]




FIGURE 1. Number and percentage of drug overdose deaths involving* illicitly manufactured fentanyls, † by month and xylazine detection or co-involvement — State Unintentional Drug Overdose Reporting System, 21 jurisdictions, January 2019–June 2022

PURPOSE

Addressing the rapidly evolving overdose crisis, driven by the increasing presence of potent synthetic opioids like sufentanil and naloxone-resistant substances such as xylazine and synthetic benzodiazepines is vital. As the illicit drug supply becomes more unpredictable and toxic, traditional overdose reversal strategies, particularly naloxone, are proving less effective.

By highlighting the pharmacological challenges posed by sufentanil's high potency, prolonged action, and resistance to standard naloxone dosing, this abstract provides essential insights for clinicians, first responders, and public health officials. It emphasizes the need for revised clinical protocols, expanded harm reduction strategies, and the development of alternative or adjunct treatments. The escalating overdose crisis demands urgent adaptation in clinical protocols and harm reduction strategies to prevent further loss of life and enhance our ability to combat this evolving public health threat.

METHODS

We reviewed and summarized data from published reviews and primary sources (in English) on the topics of addressing the current overdose crisis and the role of drug supply contaminants in shaping this evolving epidemic, as well as the first-hand knowledge of a practicing physician engaged in day-to-day clinical practice. We offer a concise overview of the issue, alongside a real-world perspective on current clinical practices and the challenges they face.

FIGURE 2. Number and percentage of drug overdose deaths involving* illicitly manufactured fentanyls, † by xylazine detection or co-involvement -State Unintentional Drug Overdose Reporting System, 31 states and District of Columbia,§ January 2021–June 2022





FIGURE 3. Representative clinical photos of xylazine-associated cutaneous ulcerations: angulated ulcerations with eschar and islands of spared normal skin.



RESULTS

Sufentanil is a highly potent synthetic opioid, approximately 5–10 times more potent than fentanyl, and is approved for use as an analgesic adjunct in anesthesia and for epidural analgesia in controlled medical settings. Its emergence in the illicit drug supply is a significant concern due to its extreme potency and rapid onset, which further increases the risk of fatal overdose in the context of an already unpredictable and contaminated drug market dominated by fentanyl, fentanyl analogs, and other synthetic opioids.[1-3] The combination of sufentanil with other potent synthetic opioids and naloxone-resistant adulterants has contributed to increased morbidity and mortality, as standard opioid overdose protocols may be insufficient, and advanced airway and hemodynamic support are often required.[1-2][4-8]

Dr. Eugene Vortsman, a dual board-certified Emergency and Addiction Medicine physician with Northwell Health, shared how this shifting landscape of the opioid overdose crisis is directly affecting the workplace dynamic and his colleagues. Dr. Vortmans explained that, in the past, a single nurse and doctor would typically handle an overdose patient in the Emergency Room with just one 4-milligram dose of Naloxone/Narcan. However, today, more than five times the personnel are required, and patients are frequently transferred to the intensive care unit for recovery. Not only are resources being stretch, but the dosage and administration of the reversal agents have changed as the contaminants are either unable to be reversed or overly potent. Vortsman states sometimes these patients can be readily identified through their ulcers that are a known side effect of Xylazine, but that those who have overdosed with contaminants with not respond to reversal method and have to be intubated.

CONCLUSIONS

Clinically, the presence of sufentanil and other potent synthetic compounds necessitates updates to overdose protocols, including the use of higher or repeated naloxone dosing and prolonged patient monitoring to manage longer-lasting respiratory depression. First responders and emergency departments must be trained to recognize and treat overdoses involving multiple drug classes, especially those resistant to naloxone, like xylazine and synthetic benzodiazepines. Public health strategies must evolve to incorporate drug-checking technologies and better surveillance of the illicit supply to detect emerging threats. Harm reduction programs may need to expand beyond naloxone distribution, emphasizing education around the limitations of reversal agents and the risks of unknown drug mixtures. Finally, policymakers must consider support of investigation into novel antidotes or treatment protocols capable of addressing increasingly complex and lethal drug combinations.

Amid evolving drug adulteration—often involving synthetic opioids or novel contaminants—clinicians on the front lines are left with limited tools for real-time identification and response, highlighting the urgent need for enhanced diagnostic capabilities and alternative harm reduction strategies within acute care settings.

1. Sufentanil Citrate. FDA Drug Label.; Food and Drug Administration; Updated date: 2025-01-07
2. Treatment of Overdose in the Synthetic Opioid Era.; Skolnick P.; Pharmacology & Therapeutics. 2022;233:108019. doi:10.1016/j.pharmthera.2021.108019.
3. Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids.; Vearrier D, Grundmann O.; Journal of Clinical Pharmacology. 2021;61 Suppl 2:S70-S88. doi:10.1002/jcph.1923.
4. Illicitly Manufactured Fentanyl-Involved Overdose Deaths With Detected Xylazine - United States, January 2019-June 2022.; Kariisa M, O'Donnell J, Kumar S, Mattson CL, Goldberger BA.; MMWR. Morbidity and Mortality Weekly Report. 2023;72(26):721-727. doi:10.15585/mmwr.mm7226a4.
5. National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings.; Perrone J, Haroz R, D'Orazio J, et al.; Annals of Emergency Medicine. 2024;84(1):20-28. doi:10.1016/j.annemergmed.2024.01.041.
6. Xylazine Spreads Across the US: A Growing Component of the Increasingly Synthetic and Polysubstance Overdose Crisis.; Friedman J, Montero F, Bourgois P, et al.; Drug and Alcohol Dependence. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380.
7. Brain Oxygen Responses Induced by Opioids: Focus on Heroin, Fentanyl, and Their Adulterants.; Kiyatkin EA, Choi S.; Frontiers in Psychiatry. 2024;15:1354722. doi:10.3389/fpsyt.2024.1354722.
8. Xylazine in the Drug Supply: Emerging Threats and Lessons Learned in Areas With High Levels of Adulteration.; Quijano T, Crowell J, Eggert K, et al.; The International Journal on Drug Policy. 2023;120:104154. doi:10.1016/j.drugpo.2023.104154.

Thomas Miller, PhD³, Eugene Vortsman, DO^{1,3}, Robert Raffa, PhD^{2,3}, Joseph Pergolizzi, MD^{3,4}, Morgan King³

¹ Northwell Health, New York, NY
² Temple University (Emeritus), Philadelphia, PA; University of Arizona (Adjunct), Tucson, AZ
³ Enalare Therapeutics, Princeton, NJ
⁴ NEMA Research, Naples, FL